News

False claims about a "health emergency" in China, supposedly triggered by a viral outbreak, have been circulating on social media,...

Ruxolitinib cream, a topical Janus kinase (JAK) 1/2 inhibitor, has shown promising results in treating pediatric patients with moderate to...

France's health authorities have introduced a new, more effective shingles vaccine, Shingrix, as part of its official vaccination program, following...

Jasper Therapeutics Reports Positive Data in Chronic Urticaria StudyJasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company valued at $266 million,...

A recent study published in JAMA Dermatology sheds light on the experiences of Latine individuals living with moderate to severe...

The global prevalence of atopic dermatitis among children is expected to rise significantly over the next five decades, according to...

Inmagene Biopharmaceuticals has announced encouraging results from a Phase 2a clinical trial evaluating the use of IMG-007 for the treatment...

CAGE Bio, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for immuno-dermatological disorders, has announced the initiation of...

The oral TYK2 inhibitor demonstrates significant potential for treating active psoriatic arthritis in adults. Bristol Myers Squibb (BMS) has announced...

Eli Lilly Korea has introduced Ebglyss, a new biologic therapy designed to treat moderate-to-severe atopic dermatitis. The treatment, which comes...